Effector Therapeutics Inc Quick Ratio (EFTR) starting from the first quarter 2024 to first quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Effector Therapeutics Inc   (NASDAQ: EFTR)

Effector Therapeutics Inc 's Quick Ratio

EFTR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Effector Therapeutics Inc 's Cash & cash equivalent grew by 38.18 % in the Q1 2024 sequentially, while Current Liabilities decreased, this led to improvement in Effector Therapeutics Inc 's Quick Ratio to 0.99, Quick Ratio remained below Effector Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Effector Therapeutics Inc in first quarter 2024. While Quick Ratio total ranking has improved so far during the Q1 2024 to 1828, from total ranking in the fourth quarter 2023 at 1935.

Explain Quick Ratio?
How much Cash & cash equivalents EFTR´s has?
What are EFTR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EFTR Quick Ratio (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1
Y / Y Current Liabilities Change -4.06 % -23.98 % -5.53 % 0.74 % 931.42 %
Y / Y Cash & cash equivalent Change 33.55 % -30.18 % -46.05 % -39.03 % -58.41 %
Quick Ratio MRQ 0.99 0.71 0.75 1.05 0.71
EFTR's Total Ranking # 1828 # 1935 # 1683 # 1632 # 2161
Seq. Current Liabilities Change -0.88 % 9.36 % -0.72 % -10.85 % -21.46 %
Seq. Cash & cash equivalent Change 38.18 % 3.32 % -28.94 % 31.63 % -27.76 %



Quick Ratio first quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 371
Healthcare Sector # 681
Overall Market # 1828


Quick Ratio Statistics
High Average Low
17.85 4.85 0.57
(Sep 30 2021)   (Jun 30 2021)




Financial Statements
Effector Therapeutics Inc 's Current Liabilities $ 26 Millions Visit EFTR's Balance sheet
Effector Therapeutics Inc 's Cash & cash equivalent $ 25 Millions Visit EFTR's Balance sheet
Source of EFTR's Sales Visit EFTR's Sales by Geography


Cumulative Effector Therapeutics Inc 's Quick Ratio

EFTR's Quick Ratio for the trailling 12 Months

EFTR Quick Ratio

 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months
Y / Y Current Liabilities TTM Growth -9.55 % 17.31 % 70.38 % 163.72 % 446.5 %
Y / Y Cash & cash equivalent TTM Growth -27.46 % -45.09 % -47.98 % -45.98 % -25.92 %
Quick Ratio TTM 0.88 0.8 0.82 0.94 1.09
Total Ranking TTM # 3665 # 3582 # 3661 # 2477 # 1883
Seq. Current Liabilities TTM Growth -1.09 % -7.54 % -1.26 % 0.16 % 28.29 %
Seq. Cash & cash equivalent TTM Growth 7.95 % -9.01 % -14.69 % -13.43 % -18.29 %

Quick ratio ranking by company, industry and sector >> Back to EFTR Financial Strength Comparisons >> Go to Compare EFTR Quick Ratio to its Competitors

On the trailing twelve months basis EFTR Cash & cash equivalent grew by 33.55 % in Q1 2024 year on year, while Current Liabilities decreased to $26 millions, this led to increase in in Effector Therapeutics Inc 's Quick Ratio to 0.88, Quick Ratio remained below EFTR average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 482 other companies have achieved higher Quick Ratio than Effector Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2023 from 3582 to 3665.

Explain Quick Ratio?
How much Cash & cash equivalents EFTR´s has?
What are EFTR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 483
Healthcare Sector # 996
Within the Market # 3665


trailing twelve months Quick Ratio Statistics
High Average Low
3.07 1.71 0.8
(Sep 30 2022)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2024 MRQ Cash & cash equivalentMar 31 2024 MRQ Current Liabilities
Enveric Biosciences Inc   2.70 $ 6.356  Millions$ 2.352  Millions
Vertex Pharmaceuticals Inc  2.68 $ 10,171.300  Millions$ 3,795.900  Millions
Rein Therapeutics Inc   2.66 $ 12.042  Millions$ 4.532  Millions
Travere Therapeutics Inc   2.55 $ 441.044  Millions$ 173.229  Millions
Verrica Pharmaceuticals Inc   2.53 $ 48.939  Millions$ 19.365  Millions
Alnylam Pharmaceuticals Inc   2.51 $ 2,360.026  Millions$ 941.709  Millions
Arcturus Therapeutics Holdings Inc   2.50 $ 288.396  Millions$ 115.430  Millions
Gri Bio Inc   2.44 $ 4.091  Millions$ 1.680  Millions
Biovie Inc   2.43 $ 30.350  Millions$ 12.481  Millions
Scienture Holdings Inc   2.41 $ 3.499  Millions$ 1.452  Millions
Karyopharm Therapeutics Inc   2.41 $ 149.037  Millions$ 61.916  Millions
Cervomed Inc   2.39 $ 6.369  Millions$ 2.661  Millions
Azitra Inc   2.39 $ 3.001  Millions$ 1.258  Millions
Oncolytics Biotech Inc   2.38 $ 12.212  Millions$ 5.122  Millions
Bioxcel Therapeutics Inc   2.36 $ 74.141  Millions$ 31.481  Millions
Alterity Therapeutics Limited  2.35 $ 8.439  Millions$ 3.588  Millions
Metavia Inc   2.34 $ 15.988  Millions$ 6.825  Millions
Axsome Therapeutics Inc   2.30 $ 331.441  Millions$ 144.048  Millions
Oragenics Inc   2.28 $ 2.072  Millions$ 0.909  Millions
Imunon Inc   2.27 $ 9.809  Millions$ 4.316  Millions
Cue Biopharma Inc   2.27 $ 41.029  Millions$ 18.090  Millions
Avenue Therapeutics Inc   2.26 $ 3.194  Millions$ 1.412  Millions
Adagene Inc   2.23 $ 85.195  Millions$ 38.185  Millions
Hutchmed china Limited  2.22 $ 836.110  Millions$ 376.562  Millions
Genprex Inc   2.16 $ 8.217  Millions$ 3.808  Millions
Gt Biopharma Inc   2.13 $ 9.807  Millions$ 4.600  Millions
Transcode Therapeutics Inc   2.12 $ 5.026  Millions$ 2.367  Millions
Ensysce Biosciences Inc   2.08 $ 3.404  Millions$ 1.636  Millions
Tg Therapeutics Inc   2.07 $ 206.711  Millions$ 99.684  Millions
Evolus Inc   2.07 $ 96.958  Millions$ 46.801  Millions

Date modified: 2026-09-08T15:11:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.